Supernus Pharmaceuticals | SUPN - Current Liabilities


Supernus Pharmaceuticals reported $330.63M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Abbott USD 14.58B 1.14B Sep/2025
ANI Pharmaceuticals USD 270.56M 33.72M Sep/2025
Aurora Cannabis CAD 124.12M 32.76M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Canopy Growth CAD 81.1M 17.56M Sep/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Eisai JPY 378.25B 33.36B Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Novo Nordisk DKK 234.36B 26.84B Sep/2025
Pacira USD 107.08M 206.09M Sep/2025
Perrigo USD 1.15B 19.2M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Supernus Pharmaceuticals USD 330.63M 44.27M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025
Xeris Pharmaceuticals USD 116.2M 21.03M Sep/2025